Safety and Efficacy of AL-53817 Nasal Spray Solution in Ragweed Sensitive Subjects in an Environmental Exposure Chamber (EEC)

Trial Profile

Safety and Efficacy of AL-53817 Nasal Spray Solution in Ragweed Sensitive Subjects in an Environmental Exposure Chamber (EEC)

Completed
Phase of Trial: Phase I

Latest Information Update: 17 May 2013

At a glance

  • Drugs AL 53817 (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Oct 2011 New trial record
    • 18 Oct 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top